EMITF - Elbit Imaging Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
1.0000
0.0000 (0.00%)
At close: 12:28PM EDT
Stock chart is not supported by your current browser
Previous Close1.0000
Open1.0000
Bid0.0000 x 1200
Ask0.0000 x 900
Day's Range0.8100 - 1.0000
52 Week Range0.6800 - 2.8000
Volume1,501
Avg. Volume7,535
Market Cap7.924M
Beta (3Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-8.3240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2008-05-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    ELBIT IMAGING ANNOUNCES UPDATE REGARDING THE AGREEMENT FOR THE SALE OF UP TO 25% OF THE SHARE CAPITAL OF ELBIT MEDICAL LTD.

    Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today, further to its press release dated February 7, 2019, regarding the Share Purchase Agreement ("SPA") with an SPV related to the Exigent Capital Group for the sale of between 3,760,417 ordinary shares of Elbit Medical Technologies Ltd. ("Elbit Medical") (1.6% of its outstanding share capital) and 57,968,760 ordinary shares of Elbit Medical (25% of its outstanding share capital), that the parties have agreed to postpone the Initial Closing of the SPA to March 27, 2019 (instead of March 18, 2019). This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire2 days ago

    ELBIT IMAGING ANNOUNCES UPDATE REGARDING THE AGREEMENT TO SELL ITS HOLDINGS IN THE PROJECT IN BANGALORE, INDIA

    Tel Aviv, Israel, March 20, 2019 -- Elbit Imaging Ltd. (“EI” or the “Company”) (TASE, NASDAQ: EMITF) announced today, further to its press release dated March 7, 2019,.

  • GlobeNewswire18 days ago

    ELBIT IMAGING ANNOUNCES AN UPDATE REGARDING THE DISPUTE IN CONNECTION WITH THE PLOT IN CHENNAI, INDIA

    Tel Aviv, Israel, March 04, 2019 -- Elbit Imaging Ltd. (the “Company”) (TASE, NASDAQ: EMITF) announced today, further to its press release dated February 11, 2019, regarding.

  • GlobeNewswire25 days ago

    ELBIT IMAGING LTD. ANNOUNCES EXPANSION OF POSITIVE INSURANCE FOR INSIGHTEC’S MR-GUIDED FOCUSED ULTRASOUND TREATMENT FOR ESSENTIAL TREMOR

    Tel Aviv, Israel, Feb. 25, 2019 -- Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today, further to its press release dated November 12, 2018,.

  • GlobeNewswire29 days ago

    ELBIT IMAGING LTD. ANNOUNCES ADDITIONAL BUYBACK OF NOTES SERIES I

    Tel Aviv, Israel, Feb. 21, 2019 --  Elbit Imaging Ltd. (“EI” or the “Company”) (TASE, NASDAQ: EMITF) announced today, further to its press release dated February 14, 2019,.

  • GlobeNewswire29 days ago

    ELBIT IMAGING ANNOUNCES NEW DATA FROM GAMIDA CELL'S NAM-NK AND NICORD® PROGRAMS AT 2019 TCT ANNUAL MEETING

    Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) (“Elbit” or the “Company”) announced today, further to its press release dated January 28, 2019, that on February 20, 2019, Gamida Cell Ltd. (GMDA) (“Gamida”), an indirect shareholding of the Company, has presented new data from its NAM-NK study, which are natural killer cells that have been expanded using Gamida's propriety nicotinamide-based, and from its NiCord® study. The data was presented at the 2019 Transplantation & Cellular Therapy (TCT) Meeting of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place in Houston, Texas. The safety and activity of NAM-NK is currently being evaluated in a Phase 1 dose-escalation study.

  • GlobeNewswirelast month

    ELBIT IMAGING ANNOUNCES THE SIGNING OF COLLABORATION AGREEMENT BETWEEN GAMIDA CELL AND EDITAS MEDICINE, INC.

    Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) (“Elbit” or the “Company”) announced today, that Gamida Cell Ltd. (GMDA) (“Gamida”), an indirect shareholding of the Company, has announced the signing of an agreement with Editas Medicine, Inc ("Editas") to evaluate the potential use of Editas's CRISPR technology to edit NAM-NK cells, which are natural killer cells that have been expanded using Gamida's propriety nicotinamide-based, or NAM, technology, that could be used to improve the treatment of hematologic malignancies and solid tumors. Under the terms of the agreement, Gamida and Editas will engage in joint research to evaluate unnamed targets by combining the companies' technologies, and evaluate the tumor-killing properties of NAM-NK cells using edited cells by Editas' technology and unedited cells, further to the initial results from Phase I study of NAM-NK to patients with multiple myeloma and non-Hodgkin lymphoma as published by the Company1.

  • GlobeNewswirelast month

    ELBIT IMAGING ANNOUNCES AN UPDATE REGARDING THE TRANSACTION FOR THE SALE OF THE PLOT IN CHENNAI, INDIA

    Tel Aviv, Israel, Feb. 11, 2019 -- Elbit Imaging Ltd. (the “Company”) (TASE, NASDAQ: EMITF) announced today, further to its press releases dated October 18, 2018, November 7,.

  • GlobeNewswirelast month

    ELBIT IMAGING ANNOUNCES SUSPENSION OF TRADING OF ITS ORDINARY SHARES ON NASDAQ

    Elbit Imaging Ltd. (“EI” or the “Company”) (TASE, NASDAQ: EMITF) announced today that it received a letter, dated February 7, 2019, from the Nasdaq Hearings Panel (the “Panel”) of The NASDAQ Stock Market (“Nasdaq”) informing the Company that the Panel has determined to delist the Company’s ordinary shares from the Nasdaq and will suspend trading in the shares effective at the open of business on February 11, 2019. As previously announced, Nasdaq had previously informed the Company that it did not meet Nasdaq Listing Rule 5450(b)(3)(C) (under which the Company must maintain a minimum market value of its publicly held shares of $15,000,000 for 30 consecutive business days), and that the Company would be subject to delisting if such requirements were not met within a certain time period.

  • GlobeNewswirelast month

    ELBIT IMAGING ANNOUNCES THE SIGNING OF AN AGREEMENT FOR THE SALE OF UP TO 25% OF THE SHARE CAPITAL OF ELBIT MEDICAL LTD.

    Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today that it has signed a Share Purchase Agreement ("SPA") with an SPV related to the Exigent Capital Group ("SPV") for the sale of between 3,760,417 ordinary shares of Elbit Medical Technologies Ltd. ("Elbit Medical") (1.6% of its outstanding share capital) and 57,968,760 ordinary shares of Elbit Medical (25% of its outstanding share capital) (the “Maximum Quantity”). Under the terms of the SPA, the SPV is to purchase an aggregate number of between 3,760,417 and 28,984,380 shares of Elbit Medical for a price per share of NIS 0.96 ($0.26 based on the NIS-US$ representative rate of exchange as of today) on or before March 18, 2019 (the "Initial Closing").

  • GlobeNewswire2 months ago

    ELBIT IMAGING ANNOUNCES UPDATE REGARDING THE AGREEMENT TO SELL ITS HOLDINGS IN THE PROJECT INBANGALORE, INDIA

    Tel Aviv, Israel, Feb. 04, 2019 -- Elbit Imaging Ltd. (“EI” or the “Company”) (TASE, NASDAQ: EMITF) announced today, further to its press release dated December 13, 2018,.

  • GlobeNewswire2 months ago

    ELBIT IMAGING LTD. ANNOUNCES FIRST GLIOBLASTOMA PATIENT COMPLETED CHEMOTHERAPY CYCLES WITH BLOOD BRAIN BARRIER DISRUPTION USING INSIGHTEC'S EXABLATE NEURO

    Tel Aviv, Israel, Jan. 30, 2019 -- Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today that Insightec Ltd. ("Insightec") and the Brain Research....

  • GlobeNewswire2 months ago

    ELBIT IMAGING ANNOUNCES DATA FROM GAMIDA CELL'S NAM-NK AND NICORD® PROGRAMS TO BE PRESENTED AT 2019 TCT ANNUAL MEETING

    Tel Aviv, Israel, Jan. 28, 2019 -- Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) (“Elbit”) announced today, further to its press releases dated December 3, 2018  and June 25, 2018,.

  • GlobeNewswire2 months ago

    ELBIT IMAGING ANNOUNCES UPDATE REGARDING THE TRANSACTION FOR THE SALE OF THE PLOT IN CHENNAI, INDIA

    Tel Aviv, Israel, Jan. 14, 2019 -- Elbit Imaging Ltd. (the “Company”) (TASE, NASDAQ: EMITF) announced today, further to its press releases dated October 18, 2018, November 7,.

  • GlobeNewswire2 months ago

    ELBIT IMAGING ANNOUNCES UPDATE REGARDING THE AGREEMENT TO SELL ITS PROJECT IN KOCHI, INDIA

    The Company expects that this amount will be paid within a few weeks. The Company will update regarding any new developments. The information detailed above, concerning the realization of transaction to sell its project in Kochi, India, is a forward-looking statement.

  • GlobeNewswire3 months ago

    ELBIT IMAGING ANNOUNCES HEARING’S PANEL DATE

    Tel Aviv, Israel, Jan. 02, 2019 --  Elbit Imaging Ltd. (“EI” or the “Company”) (TASE, NASDAQ: EMITF) announced today that The Nasdaq Stock Market (“Nasdaq”) granted the.

  • GlobeNewswire3 months ago

    ELBIT IMAGING ANNOUNCES RECEIPT OF DELISTING DETERMINATION FROM NASDAQ STAFF; COMPANY TO REQUEST HEARING

    Elbit Imaging Ltd. (“EI” or the “Company”) (TASE, NASDAQ: EMITF) announced today that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (the “Staff“) indicating that the Company did not meet the Staff’s December 24, 2018 deadline to regain compliance with Nasdaq Listing Rule 5450(b)(3)(C) due to the Company’s failure to maintain a minimum market value of its publicly held shares of $15,000,000 for 30 consecutive business days. As a result, the Company would be subject to delisting on January 4, 2019 unless it requests a hearing before a Nasdaq Hearings Panel (the “Panel“). As previously disclosed, the Company intends to request a hearing before the Panel at which it will present its plan of compliance and request a further extension of time.

  • GlobeNewswire3 months ago

    ELBIT IMAGING ANNOUNCES IT IS NO LONGER THE CONTROLLING SHAREHOLDER OF PLAZA CENTERS N.V.

    Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today that it has signed a trust agreement according to which the Company will deposit its shares of Plaza Centers N.V (the "Shares" and "Plaza", respectively) with a trustee. In accordance with the trust agreement, Elbit retains the right to receive any and all rights in connection with the Shares, other than the voting rights which are vested with the trustee for all matters and purposes effective from December 18, 2018. In addition, Elbit may instruct the trustee, from time to time, to sell all or any portion of the Shares.

  • GlobeNewswire3 months ago

    ELBIT IMAGING LTD. ANNOUNCES THAT INSIGHTEC RECEIVED FDA APPROVAL OF EXABLATE NEURO FOR THE TREATMENT OF TREMOR-DOMINANT PARKINSON'S DISEASE

    Tel Aviv, Israel, Dec. 19, 2018 -- Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today that Insightec Ltd. ("Insightec") informed that the....